Xylocydine, a novel CDK7 inhibitor, can effectively induce significant cell growth inhibition and apoptosis in vitro and in vivo, making it a good candidate for HCC treatment (Cho et al., 2010). This evidence concerns the gene CDK7 and hepatocellular carcinoma.